Enulose

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enulose

What is Enulose?

Enulose is a synthetic sugar solution used primarily in the management and prevention of portal-systemic encephalopathy, a condition that affects brain function in individuals with severe liver disease. Chemically known as lactulose, it is a disaccharide consisting of fructose and galactose.

How Enulose Works

Enulose functions as an acidifying agent in the colon. When consumed, it is not broken down by the enzymes in the human small intestine. Instead, it travels to the large intestine where it is metabolized by resident bacteria into low-molecular-weight organic acids, such as lactic acid and acetic acid.

This process performs two primary functions:

  • Ammonia Reduction: The acidification of the colonic contents converts ammonia (NH3) into ammonium ions (NH4^+). Because ammonium ions are charged, they cannot be easily reabsorbed into the bloodstream. This effectively traps the ammonia in the bowel so it can be eliminated from the body.
  • Osmotic Effect: The presence of the organic acids increases osmotic pressure within the colon. This draws water into the stool, softening it and stimulating bowel movements, which further aids in the rapid clearance of nitrogenous waste products.

Therapeutic Purpose

By lowering the levels of ammonia in the blood, Enulose helps to improve the mental state and neurological function of patients experiencing hepatic encephalopathy. It is utilized to help reduce symptoms such as confusion, tremors, and decreased consciousness associated with liver dysfunction.

Regulatory References

  1. FDA Approved Drug Products: Lactulose
  2. Lactulose - StatPearls - NCBI Bookshelf

What side effects are possible with Enulose?

Official Regulatory Safety Profile

The possible side effects and safety characteristics of Enulose (lactulose) are officially classified based on their frequency and the physiological systems affected, as documented in government regulatory sources. Adverse reactions are primarily concentrated within the Gastrointestinal Disorders system.


Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Very Common (gt 1 in 10) Diarrhea (especially at high doses)
Common (le 1 in 10) Flatulence (wind), Nausea, Vomiting, Abdominal pain
Uncommon (le 1 in 100) Electrolyte imbalance, Fluid loss

Serious Adverse Reactions and Safety Constraints

The regulatory labeling defines more serious, though less frequent, outcomes and critical constraints. Disturbances are grouped under Metabolism and Nutrition Disorders. The most significant documented safety concern is the risk of Electrolyte Imbalance and Dehydration (e.g., Hypokalemia, Hypernatremia) that may result from severe, prolonged diarrhea, typically during high-dose treatment for hepatic encephalopathy.

Time-Related Patterns: Flatulence and abdominal discomfort are most commonly reported during the initial days of treatment and are generally transient. The risk of fluid and electrolyte disturbance is associated with prolonged exposure at high doses, necessitating professional oversight in certain cases.

Population and Condition Restrictions: Enulose is officially contraindicated in patients with Galactosemia or those with a confirmed Gastrointestinal Obstruction or perforation risk. Caution is required for patients with diabetes or for elderly/debilitated patients on long-term, high-dose therapy, where periodic monitoring of serum electrolytes is recommended in official documents.

Overdose and Emergency Response

Official Overdose Manifestations

Overdose of Enulose (Lactulose) is defined by the consequences of excessive osmotic activity in the gut, rather than direct systemic toxicity. The primary officially documented manifestations are severe and protracted diarrhea accompanied by abdominal cramps. Excessive dosage may also lead to the occurrence of nausea and vomiting.

When to Seek Urgent Medical Help

The principal danger from overdose is the resulting physiological disturbance due to fluid imbalance. Excessive fluid loss creates a significant risk of severe electrolyte imbalance, particularly hypokalemia (low potassium) and hypernatremia (high sodium). This risk of severe complication is officially noted to be heightened in elderly and debilitated patients.

If severe, prolonged diarrhea or any signs of significant electrolyte disturbance occur, the medication must be terminated immediately, and urgent medical attention should be sought.

Management and Antidote Status

Official regulatory documents state that no specific antidote is known for Lactulose overdose. Management is symptomatic and supportive, and the required medical procedure involves the clinical correction of electrolyte disturbances resulting from the overdose, following the termination of the medication.

Therapeutic Uses of Enulose

What Enulose Treats: Main Uses and Benefits

The therapeutic role of Enulose (lactulose) is commonly used across two therapeutic areas: managing chronic gastrointestinal issues and providing supportive care for a specific liver condition. It is applied in scenarios where additional management of discomfort is required, and may help support general well-being during symptomatic phases.

Enulose is commonly used to help with conditions characterized by periods of heightened symptoms, specifically constipation and hepatic encephalopathy (HE).


Managing Symptomatic Discomfort and Functional Strain

This domain covers the use of Enulose in situations involving certain distressing symptoms related to chronic constipation. It helps address symptom clusters that may become intense or disruptive and interfere with daily functioning. It is relevant for easing short-term symptomatic assistance and contributing to improved day-to-day comfort during periods of heightened symptoms.

“Applied across domains where additional symptomatic support is needed.”

Quick Fact: Used for managing Symptoms that Interfere with Daily Functioning.


Supportive Care for Hepatic Encephalopathy Episodes

Enulose is also applied in addressing a more complex condition category known as hepatic encephalopathy (HE), which is associated with systemic or localized discomfort. Relevant in contexts involving heightened systemic burden, this use provides support that helps ease the overall symptom burden associated with acute or recurrent episodes, assisting with maintaining functional stability during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Enulose? Official Eligibility

The eligibility profile for Enulose (lactulose) is defined by official population constraints detailed in regulatory labeling. This section describes who is formally allowed to use the medicine and the conditions that prohibit its use.


Contraindications: Who Must Not Use Enulose

Enulose is strictly contraindicated for individuals with specific metabolic or gastrointestinal conditions:

  • Galactosemia: A contraindication exists for patients who require a low-galactose diet.
  • Gastrointestinal Obstruction or Perforation: Prohibited in cases of mechanical blockage or where there is a risk of GI tract perforation (e.g., severe acute inflammatory bowel disease).
  • Hypersensitivity: Must not be used by patients with a known allergy to lactulose or its components.

Use in Specific Populations

Population Group Regulatory Status
Adults Generally approved for use.
Children & Infants Use is exceptional and requires medical supervision.
Pregnant / Breastfeeding Use is generally permitted as systemic exposure is negligible.
Diabetic Patients Use with caution due to the trace sugar content, especially at high doses.
Pediatric HE Treatment Efficacy and safety are not established for hepatic encephalopathy in children.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents indicate that the interaction profile for Enulose (Lactulose) is focused on agents that affect the local environment of the colon, rather than systemic metabolic (CYP450) pathways, given the drug’s minimal systemic absorption. The official constraints address pharmacodynamic effects and local efficacy.

Pharmacodynamic and Local Efficacy Interactions

The most significant interaction involves a pharmacodynamic additive effect with other laxatives. Co-administration is formally noted to increase the risk of severe diarrhea, which may lead to clinically significant dehydration and electrolyte imbalance. This risk is particularly noted in official documents for the elderly and patients with pre-existing electrolyte abnormalities.

Restricted Combinations and Administration Timing

  • Anti-acid agents (Antacids) should generally not be taken concurrently with Enulose. Nonabsorbable antacids may interfere with the necessary decrease in colonic pH required for the drug's ammonia-detoxifying effect, potentially leading to a lack of the desired therapeutic response.
  • The therapeutic action of Enulose relies on colonic bacteria. Therefore, the co-administration of certain anti-infective agents may reduce the population of these necessary bacteria, which could cause an inadequate therapeutic response.
  • Caution is given that Lactulose, by altering colonic pH and transit time, may impact the function of pH-dependent oral mesalazine preparations, affecting the local delivery or disposition of the other medicine.

Substance and Other Interactions

The regulatory context notes that combination with alcohol may further increase the risk of fluid loss, heightening the potential for dehydration when taken with the osmotic effects of Lactulose. Additionally, some official sources note that loop diuretics may enhance the risk of hypokalemia when used alongside prolonged laxative therapy.

Mechanism of Action

How Enulose Works

The mechanism of Enulose (lactulose) involves action that is peripheral and confined to the large intestine. The drug acts as an unabsorbed substrate for resident colonic bacteria, which metabolize the disaccharide into short-chain organic acids.

Mechanism 1: Osmotic Modulation

This bacterial metabolism creates two simultaneous physiological effects. Firstly, the increased presence of unabsorbed solute and its acidic metabolites establishes a strong osmotic gradient within the colon lumen. This gradient facilitates the passive movement of water from the systemic circulation into the intestinal lumen, increasing the volume and liquidity of the colonic contents.

Mechanism 2: Nitrogenous Compound Trapping

Secondly, the organic acid production significantly lowers the pH of the large intestine. This acidic environment mediates the conversion of freely diffusible ammonia ( NH3) into the charged, non-absorbable ammonium ion ( NH4^+). This ion-trapping process limits the compound's passive diffusion across the intestinal wall, resulting in its fecal clearance.

Dosage and Administration Information

The administration of Enulose (lactulose solution) is determined by the specific use scenario, involving distinct routes, doses, and frequency patterns. The solution is used via the oral route for all primary indications. However, it is also utilized for rectal administration as a retention enema when used in the acute management of severe hepatic encephalopathy (HE), such as impending coma.

Oral administration is flexible: the solution may be taken undiluted or mixed with water, fruit juice, or milk, and is typically taken at the same time each day.

Dosing is tailored to the condition and response:

Indication Administration Regimen (Adult) Frequency Pattern
Chronic Constipation 15 mL to 30 mL (10 g to 20 g lactulose) Once daily or in two divided doses
Hepatic Encephalopathy (HE) 30 mL to 45 mL (20 g to 30 g lactulose) Three or four times daily (initial)

For both uses, the dose is adjusted until the specific physiological target of producing two to three soft stools daily is achieved. The duration of use also differs: HE management requires continuous, long-term therapy, whereas constipation use may be shorter-term. No special dose adjustments are mandated for older adults or patients with kidney or liver impairment, as the drug's systemic absorption is negligible. The rectal enema requires 300 mL of the solution to be diluted with 700 mL of water or saline and retained for 30 to 60 minutes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Enulose (Lactulose)


1. Research Evidence for Chronic Constipation

The research base for Enulose (lactulose) in chronic constipation relies on findings from short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time and are subsequently aggregated into systematic reviews and meta-analyses. The studies examined the agent's role in adult patients with functional limitations.

Researchers primarily studied outcomes related to measurable changes in physical function. They monitored objective markers of bowel function, including the frequency of spontaneous bowel movements per week and changes in stool consistency using standardized scales. Study findings reported measurements of changes in these parameters over the defined time intervals of a few weeks. The findings contribute to the broader evidence landscape by describing observed changes in study groups.

However, the existing research provides limited insight into the long-term management of this condition. Follow-up durations were limited in many of the core trials, meaning long-term effects are not fully established. Comparative evidence is lacking for a full assessment against some of the newer osmotic agents that have entered the market since the initial studies were conducted.


2. Research Evidence for Hepatic Encephalopathy (HE)

This section summarizes the structure of the research base for studies exploring the agent’s role in Hepatic Encephalopathy (HE), detailing the trials and systematic reviews that have investigated clinical and neurological status, and studies examining the outcomes related to HE recurrence in patients with cirrhosis. The research has explored the agent’s role in conditions associated with acute or disruptive episodes, particularly in adult patients with underlying cirrhosis. This research has involved RCTs comparing the agent to control groups or other standard therapies, and these results are summarized in extensive systematic reviews and meta-analyses. Studies were conducted during periods of increased symptom activity as well as for long-term maintenance.

Research monitored outcomes reflecting systemic imbalance. Studies monitored objective measures, including neurological and clinical status using specialized scales designed for HE, as well as changes observed in blood ammonia levels—a key biomarker. For patients managed over extended periods, research examined the frequency of overt HE recurrence. Studies reported measurements of how symptoms evolved in the observed populations during both acute episodes and throughout long-term maintenance phases.

Ethical constraints present a limitation in this field, as it is challenging to conduct modern, large-scale placebo-controlled trials for the treatment of overt HE, where the agent is observed in many settings as standard care. While research is ongoing, findings were mixed in some trials that directly compared this agent to specific antibiotic regimens used for HE management.


3. Long-Term Studies and Follow-Up Data

Available research for Enulose includes two distinct types of follow-up duration, which apply differently to the two main indications. For chronic constipation, the evidence remains focused on short-term outcomes over several days to weeks, as this is typically sufficient to assess the onset of a functional change.

In contrast, studies related to Hepatic Encephalopathy often require long-term follow-up, sometimes extending to six months or a year. These longer studies were conducted to examine the outcomes related to the prevention of HE episodes. Research provides context on these extended-duration patterns, but for both indications, data describing outcomes that span many years are less detailed in the high-level scientific summaries.


4. Studies in Special Populations

Most of the primary clinical evidence applies only to the adult populations studied in the key RCTs for both constipation and HE. While the agent has been evaluated in certain groups of children, data for specific pediatric populations, pregnancy-related groups, or older adults with unique comorbidities remains limited and heterogeneous.

Studies exploring short-term symptom changes in these special populations exist, but the findings often come from smaller cohorts or limited subgroup analyses. The results apply only to the populations studied, and data for certain groups remain insufficient to draw broad conclusions across all demographics.


5. Summary of Research Uncertainty and Gaps

The body of research for Enulose establishes a base of evidence, yet certain areas require further study. Specifically, the long-term effects are not fully established for chronic functional constipation, where follow-up durations were limited in the primary trials.

Additionally, while the agent has been extensively studied, comparative evidence is lacking for direct, head-to-head comparisons against all newer-generation agents in both the laxative and HE fields. This means that a complete understanding of relative performance and subgroup findings is still uncertain, and the existing research contributes to the broader evidence landscape without providing definitive, individualized predictions.

Frequently Asked Questions (FAQ)

Common questions about Enulose (FAQ)


Q: How quickly should I expect Enulose to start working for constipation?

Since Enulose must reach the colon and be processed there to have an effect, the official prescribing information indicates that the desired change in bowel movement may take 24 to 48 hours to occur. This time frame allows the medicine to complete its action in the large intestine.


Q: What's the difference between the Enulose syrup and other forms of lactulose?

Enulose is simply one of the brand names for the active ingredient, lactulose solution (often called a syrup). While other brands of lactulose exist, the official regulatory information does not detail specific differences in composition or efficacy between them.


Q: Can Enulose be taken with food, or does it have to be on an empty stomach?

The official guidance for oral administration is flexible. Regulatory documents note that the solution may be taken undiluted or mixed with liquids like water, fruit juice, or milk to improve its acceptability. This implies the timing can be flexible and is not strictly dependent on meals.


Q: Do I need a prescription to buy Enulose?

Yes, Enulose (lactulose solution) is officially designated as a Human Prescription Drug (Rx) in the United States. It requires a prescription from a licensed healthcare provider for dispensing.


Q: How long does the laxative effect of Enulose usually last?

Official prescribing information does not specifically quantify the duration of the laxative effect from a single dose. However, the drug is designed to work in the colon and is minimally absorbed, with almost all absorbed material excreted within 24 hours.


Q: What happens if I miss a dose of Enulose?

Information from patient guidance documents describes a general practice for missed doses: if a dose is missed, it can be taken when remembered, unless it is close to the time for the next scheduled dose. In such cases, it is advised in guidance to continue with the regular schedule, avoiding taking a double dose.


Q: Are there any common over-the-counter medicines that interact with Enulose?

Regulatory information cautions against using other laxatives at the same time, especially during initial therapy for hepatic encephalopathy, as this significantly increases the risk of severe diarrhea. Additionally, nonabsorbable antacids are noted in official documents as agents that should be used with caution because they may interfere with the medicine’s ability to lower the pH in the colon, potentially reducing its therapeutic effect.


Q: Does Enulose affect blood sugar levels?

Official precautions note that the solution contains small amounts of other sugars, including galactose and lactose, as manufacturing byproducts. Because of this content, official regulatory documentation states that this medicine should be used with caution in patients who have diabetes.


Q: Is Enulose safe for older adults or the elderly?

Official guidelines indicate that for elderly or debilitated patients who are receiving high-dose therapy for more than six months, it is recommended to have serum electrolytes measured periodically. This step is a standard precaution to monitor for potential changes caused by prolonged use.


Q: Why do some people say Enulose has a very sweet taste?

Enulose is a solution whose active ingredient, lactulose, is a synthetic disaccharide (a sugar molecule). The product’s composition of lactulose along with trace amounts of other sugar byproducts contributes to its noticeably sweet flavor.


Q: Is there a maximum amount of time someone should take Enulose continuously?

Regulatory documents indicate that long-term therapy is used for the management of hepatic encephalopathy (HE). For patients who continue therapy for more than six months, official guidelines recommend periodic measurement of serum electrolytes to monitor for potential imbalances.


Q: Are there any specific foods or drinks to avoid while taking Enulose?

The primary food-related restriction noted in official documents is that the medicine is strictly contraindicated for patients who require a low-galactose diet due to the product's trace galactose content.


Q: Does Enulose need to be refrigerated after opening?

No. Official product information states that Enulose should be stored at controlled room temperature (e.g., 20 to 25C or 68 to 77F). The solution must be kept from freezing, and prolonged exposure to high heat or direct light should also be avoided to maintain the medicine's quality.


Q: Can children take Enulose for constipation?

According to the prescribing information, the safety and effectiveness of Enulose in pediatric patients for all indications have not been established. Specific data on its use in very young children and adolescents remains limited in the primary regulatory documentation.


Q: Can Enulose cause dehydration if you're not drinking enough water?

Official safety information states that excessive dosage can lead to severe diarrhea, and as a complication of this, fluid loss and dehydration are risks. Regulatory documents mention fluid loss and dehydration as risks associated with excessive diarrhea.


Q: Can Enulose be given through a tube feeding?

The official regulatory documents and label only specify two routes of administration: oral (by mouth) and rectal (as an enema) for acute use. The use of the solution via other methods, such as tube feeding, is not formally addressed in the official prescribing information.


Q: Can Enulose cause electrolyte imbalances?

Yes. Excessive dosage of the medicine can lead to diarrhea, and as a complication of this, the official safety profile lists the potential for fluid loss and serious electrolyte imbalances. Examples include hypokalemia (low potassium) and hypernatremia (high sodium).


Q: Is Enulose safe to use during pregnancy or while breastfeeding?

Regulatory information indicates that the drug should be used during pregnancy only when clearly needed. Caution is also advised when administering the medicine to a nursing woman, as it is not known if the drug is excreted in human milk.


Q: Does Enulose have any known drug interactions with common heart medications?

The official drug interactions section does not list specific common heart medications. However, any drug that causes severe diarrhea and subsequent electrolyte imbalance could potentially affect patients taking medicines sensitive to changes in potassium or sodium levels.

How should Enulose be stored and disposed of?

How to Store and Dispose of Enulose?

Official regulatory guidelines define strict conditions for the storage and disposal of Enulose (Lactulose Solution) to ensure its stability and environmental safety.

Required Storage Conditions

Enulose must be stored at controlled room temperature, generally between 15 to 30C (59 to 86F), and should be kept away from direct light and excess heat or moisture. It is mandatory to keep the container tightly closed and out of the sight and reach of children, utilizing its child-resistant closure. The solution must not be frozen, as this can affect its physical state, and it should not be used if extreme darkening or cloudiness occurs due to improper storage.

Disposal Instructions

Disposing of Enulose must follow specific environmental rules. It is prohibited to throw the medication away via household waste or wastewater (e.g., do not flush down the toilet). Instead, patients are directed to ask a healthcare professional or pharmacist how to discard unused or expired medicine properly, often through a formal medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enulose found in:

A-Z Index: